[go: up one dir, main page]

CL2016001794A1 - Metodo para administrar tasimelteon a un paciente humano que incluye la administración oral de una dosis efectiva en condiciones de ayuno para tratar un trastorno del ritmo circadiano o un trastorno del sueño, como el trastorno del sueño-vigilia diferente a 24 horas no-24 metodo para acortar el tmax del tasimelteon en un paciente humano que está siendo tratado con tasimelteon. - Google Patents

Metodo para administrar tasimelteon a un paciente humano que incluye la administración oral de una dosis efectiva en condiciones de ayuno para tratar un trastorno del ritmo circadiano o un trastorno del sueño, como el trastorno del sueño-vigilia diferente a 24 horas no-24 metodo para acortar el tmax del tasimelteon en un paciente humano que está siendo tratado con tasimelteon.

Info

Publication number
CL2016001794A1
CL2016001794A1 CL2016001794A CL2016001794A CL2016001794A1 CL 2016001794 A1 CL2016001794 A1 CL 2016001794A1 CL 2016001794 A CL2016001794 A CL 2016001794A CL 2016001794 A CL2016001794 A CL 2016001794A CL 2016001794 A1 CL2016001794 A1 CL 2016001794A1
Authority
CL
Chile
Prior art keywords
tasimelteon
disorder
human patient
sleep
tmax
Prior art date
Application number
CL2016001794A
Other languages
English (en)
Inventor
Marlene Michelle Dressman
Mihael H Polymeropoulos
Paolo Baroldi
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53520399&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016001794(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of CL2016001794A1 publication Critical patent/CL2016001794A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

METODO PARA ADMINISTRAR TASIMELTEON A UN PACIENTE HUMANO QUE INCLUYE LA ADMINISTRACIÓN ORAL DE UNA DOSIS EFECTIVA EN CONDICIONES DE AYUNO PARA TRATAR UN TRASTORNO DEL RITMO CIRCADIANO O UN TRASTORNO DEL SUEÑO, COMO EL TRASTORNO DEL SUEÑO-VIGILIA DIFERENTE A 24 HORAS No-24 METODO PARA ACORTAR EL Tmax DEL TASIMELTEON EN UN PACIENTE HUMANO QUE ESTÁ SIENDO TRATADO CON TASIMELTEON.
CL2016001794A 2014-01-14 2016-07-13 Metodo para administrar tasimelteon a un paciente humano que incluye la administración oral de una dosis efectiva en condiciones de ayuno para tratar un trastorno del ritmo circadiano o un trastorno del sueño, como el trastorno del sueño-vigilia diferente a 24 horas no-24 metodo para acortar el tmax del tasimelteon en un paciente humano que está siendo tratado con tasimelteon. CL2016001794A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461927465P 2014-01-14 2014-01-14
US14/511,669 US10376487B2 (en) 2013-11-12 2014-10-10 Method of treatment

Publications (1)

Publication Number Publication Date
CL2016001794A1 true CL2016001794A1 (es) 2017-04-28

Family

ID=53520399

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001794A CL2016001794A1 (es) 2014-01-14 2016-07-13 Metodo para administrar tasimelteon a un paciente humano que incluye la administración oral de una dosis efectiva en condiciones de ayuno para tratar un trastorno del ritmo circadiano o un trastorno del sueño, como el trastorno del sueño-vigilia diferente a 24 horas no-24 metodo para acortar el tmax del tasimelteon en un paciente humano que está siendo tratado con tasimelteon.

Country Status (19)

Country Link
US (4) US10376487B2 (es)
EP (1) EP3094322B1 (es)
JP (4) JP2017502996A (es)
KR (3) KR101970050B1 (es)
CN (2) CN107072978A (es)
AU (3) AU2015206797A1 (es)
CA (2) CA2936504C (es)
CL (1) CL2016001794A1 (es)
DK (1) DK3094322T3 (es)
ES (1) ES2805451T3 (es)
HR (1) HRP20201069T1 (es)
HU (1) HUE051244T2 (es)
IL (1) IL246676B (es)
MX (1) MX377438B (es)
NZ (1) NZ722254A (es)
PT (1) PT3094322T (es)
SI (1) SI3094322T1 (es)
WO (1) WO2015108728A1 (es)
ZA (1) ZA201605103B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101587394B1 (ko) * 2006-05-22 2016-01-21 반다 파마슈티칼즈, 인코퍼레이티드. 멜라토닌 효능제 치료
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
WO2013112949A2 (en) 2012-01-26 2013-08-01 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
SI3188727T1 (sl) * 2014-09-02 2023-03-31 Vanda Pharmaceuticals Inc. Tasimelteon za zdravljenje Smith-Magenisovega sindroma
US20210059973A1 (en) 2017-08-02 2021-03-04 Vanda Pharmaceuticals Inc. Treatment of Affective Disorders
MX2021002974A (es) * 2018-09-12 2021-05-12 Vanda Pharmaceuticals Inc Mejora del sue?o o del rendimiento despues de dormir.
IL317244A (en) * 2019-12-13 2025-01-01 Vanda Pharmaceuticals Inc Liquid formulations of tasimalteon and methods of using them
AU2022345260A1 (en) 2021-09-14 2024-04-04 Vanda Pharmaceuticals Inc. Treatment of sleep disturbances in autism spectrum disorder patients

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL50699A0 (en) 1975-10-28 1976-12-31 Ici America Inc Triazole derivatives
DE3466215D1 (en) 1983-05-18 1987-10-22 Univ Monash The use of melatonin for the manufacture of a medicament
IL79264A0 (en) 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
US4997845A (en) 1987-02-02 1991-03-05 Eli Lilly And Company β-alkylmelatonins as ovulation inhibitors
US5093352A (en) 1988-11-14 1992-03-03 Whitby Research, Inc. Antidepressant agents
US5151446A (en) 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5242941A (en) 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
US6638963B1 (en) 1990-12-04 2003-10-28 Oregon Health And Science University Methods for treating circadian rhythm disorders
IT1251544B (it) 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
US6180657B1 (en) 1993-11-18 2001-01-30 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
GB9416884D0 (en) 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
NZ298878A (en) 1995-02-01 1999-05-28 Neurim Pharma 1991 Use of melatonin to treat addiction to benzodiazepines
EP0862429A4 (en) 1995-10-24 2003-05-28 Gruenenthal Gmbh Method of adjusting the circadian rhythm of a mammal
WO1998025606A1 (en) 1996-12-10 1998-06-18 Bristol-Myers Squibb Company Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents
US5776969A (en) 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
AUPO588297A0 (en) 1997-03-26 1997-04-24 Luminis Pty Limited Mediation in melatonin production
EP1100508B8 (en) 1998-06-09 2004-01-07 Takeda Chemical Industries, Ltd. Pharmaceutical combination comprising a tricyclic compound and at least one of zolpidem, zopiclone and brotizolam for treating or preventing sleep disorders
US6562858B2 (en) 1999-05-17 2003-05-13 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating depression
US6211225B1 (en) 1999-06-30 2001-04-03 Bristol-Meyers Squibb Heterocyclic aminopyrrolidine derivatives as melatonergic agents
WO2003037337A1 (en) 2001-10-30 2003-05-08 Novartis Ag Depot formulations of iloperidone and a star polymer
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
JP2005080603A (ja) 2003-09-10 2005-03-31 Kumamoto Technology & Industry Foundation 生体リズム障害の度合の判断方法
US20050137247A1 (en) 2003-12-22 2005-06-23 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
WO2005063297A2 (en) 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
US20080280954A1 (en) 2005-07-29 2008-11-13 Vanda Pharmaceuticals, Inc Method of Improving Wakefulness
US7754902B2 (en) 2006-05-18 2010-07-13 Vanda Pharmaceuticals, Inc. Ruthenium(II) catalysts for use in stereoselective cyclopropanations
BRPI0712014A2 (pt) 2006-05-22 2011-12-27 Vanda Pharmaceuticals Inc tratamento de distérbios depressivos
KR101587394B1 (ko) * 2006-05-22 2016-01-21 반다 파마슈티칼즈, 인코퍼레이티드. 멜라토닌 효능제 치료
CA2693992C (en) 2006-07-20 2017-01-31 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
CN101557823A (zh) 2006-07-21 2009-10-14 加利福尼亚大学董事会 人内源性逆转录病毒多肽组合物和其使用方法
WO2008070795A2 (en) 2006-12-06 2008-06-12 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
ES2851177T3 (es) 2007-04-11 2021-09-03 Biomarin Pharm Inc Tetrahidrobiopterina para el tratamiento de afecciones asociadas con niveles elevados de fenilalanina
US11060144B2 (en) 2007-09-13 2021-07-13 Vanda Pharmaceuticals Inc. Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype
WO2009084023A2 (en) 2007-10-19 2009-07-09 Glenmark Generics Limited Amorphous ramelteon and process for the preparation thereof
WO2009058261A1 (en) 2007-10-31 2009-05-07 Merck & Co., Inc. Modulation of sleep with nr2b receptor antagonists
JP5558016B2 (ja) 2009-03-17 2014-07-23 株式会社 資生堂 概日リズム調整剤
WO2010115615A1 (en) 2009-04-07 2010-10-14 Duocort Pharma Ab Improved glucocorticoid therapy
WO2011009102A1 (en) 2009-07-16 2011-01-20 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
WO2013112949A2 (en) 2012-01-26 2013-08-01 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
EP3470405A1 (en) 2014-02-12 2019-04-17 Vanda Pharmaceuticals Inc. Highly purified pharmaceutical grade tasimelteon

Also Published As

Publication number Publication date
US20150196527A1 (en) 2015-07-16
CN116115551A (zh) 2023-05-16
IL246676A0 (en) 2016-08-31
AU2015206797A1 (en) 2016-08-04
KR20190040102A (ko) 2019-04-16
CN107072978A (zh) 2017-08-18
US20170087122A9 (en) 2017-03-30
CA2936504A1 (en) 2015-07-23
ZA201605103B (en) 2023-07-26
JP2023024704A (ja) 2023-02-16
EP3094322A1 (en) 2016-11-23
KR101970050B1 (ko) 2019-04-17
US11141400B2 (en) 2021-10-12
AU2020202719A1 (en) 2020-05-14
EP3094322B1 (en) 2020-04-08
RU2016133348A3 (es) 2018-09-26
WO2015108728A1 (en) 2015-07-23
US11786502B2 (en) 2023-10-17
KR102154458B1 (ko) 2020-09-09
MX377438B (es) 2025-03-10
MX2016009231A (es) 2016-10-05
NZ722254A (en) 2022-07-01
KR20160106735A (ko) 2016-09-12
US20190336470A1 (en) 2019-11-07
AU2020202719B2 (en) 2022-03-10
JP2025137763A (ja) 2025-09-19
HRP20201069T1 (hr) 2020-10-30
JP2021102634A (ja) 2021-07-15
PT3094322T (pt) 2020-07-14
US10376487B2 (en) 2019-08-13
SI3094322T1 (sl) 2020-08-31
US10610511B2 (en) 2020-04-07
KR102276569B1 (ko) 2021-07-12
AU2022201953A1 (en) 2022-04-14
US20200188346A1 (en) 2020-06-18
CA2936504C (en) 2020-10-13
ES2805451T3 (es) 2021-02-12
KR20200106094A (ko) 2020-09-10
HK1231404A1 (zh) 2017-12-22
CA3091827A1 (en) 2015-07-23
US20210379008A1 (en) 2021-12-09
DK3094322T3 (da) 2020-07-20
HUE051244T2 (hu) 2021-03-01
RU2016133348A (ru) 2018-02-20
IL246676B (en) 2020-10-29
JP2017502996A (ja) 2017-01-26

Similar Documents

Publication Publication Date Title
CL2016001794A1 (es) Metodo para administrar tasimelteon a un paciente humano que incluye la administración oral de una dosis efectiva en condiciones de ayuno para tratar un trastorno del ritmo circadiano o un trastorno del sueño, como el trastorno del sueño-vigilia diferente a 24 horas no-24 metodo para acortar el tmax del tasimelteon en un paciente humano que está siendo tratado con tasimelteon.
CY1124298T1 (el) Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet
MX2015013355A (es) Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer.
BR112016028964A2 (pt) métodos de tratamento com antagonistas contra pd-1 e pd-l1 em combinação com terapia de radiação
CR20210368A (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
PE20170302A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
CL2015001700A1 (es) Tratamiento de trastornos del ritmo circadiano
MX2017000628A (es) Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
MX380767B (es) Métodos para reducir el riesgo cardiovascular.
MX2016016137A (es) Metodos veterinarios para usar oxido nitrico en un estado de plasma para tratar condiciones medicas y enfermedades en animales.
MX2020001768A (es) Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
MX2019003703A (es) Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23.
MX395523B (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert.
MX2018013663A (es) Metodos para tratar trastornos de sueño de ritmo circadiano.
PH12017500392A1 (en) Medical treatments based on anamorelin
BR112019002945A2 (pt) terapia de combinação para o tratamento de câncer pancreático
BR112015026973A2 (pt) uso de vanoxerina no tratamento de arritmia cardíaca
EA201790220A1 (ru) Лечение симптомов, связанных с андроген-депривационной терапией
MX369090B (es) Sultiame para el tratamiento de apnea del sueño.
AR097590A1 (es) Métodos para tratar el síndrome del x frágil y trastornos relacionados
AR102494A1 (es) Métodos para tratar enfermedades oculares
MX385725B (es) Composición farmacéutica que comprende sumatriptán para tratamiento de migraña.
UA95104U (uk) Спосіб терапії хворих на негоспітальну пневмонію з супутньою хсн